BRIEF published on 05/13/2025 at 07:05, 11 months 21 days ago Innate Pharma Reports First Quarter 2025 Results Financial Results Clinical Trials Innate Pharma Sanofi Investment Lacutamab FDA
PRESS RELEASE published on 05/13/2025 at 07:00, 11 months 21 days ago Inside Information / News release on accounts, results Innate Pharma reports Q1 2025 business update with €15 million investment by Sanofi, FDA Breakthrough Therapy Designation for lacutamab, and cash position of €72.5 million FDA Financial Results Sanofi Innate Pharma Q1 2025
BRIEF published on 05/02/2025 at 15:27, 1 year ago Sanofi increases its stake in Innate Pharma Capital Actions Crossing Thresholds Sanofi Innate Pharma
BRIEF published on 04/29/2025 at 21:05, 1 year ago Innate Pharma Presents Promising Preclinical Data for IPH4502 at AACR 2025 Preclinical Data Innate Pharma IPH4502 Nectin-4 Antibody Drug Conjugate
PRESS RELEASE published on 04/29/2025 at 21:00, 1 year ago Inside Information / Other news releases Innate Pharma presents preclinical data for IPH4502, a Nectin-4 targeting ADC, showing superior anti-tumor efficacy in multiple cancer models at AACR 2025 Annual Meeting Preclinical Data Innate Pharma IPH4502 AACR 2025 Nectin-4 ADC
BRIEF published on 04/24/2025 at 07:40, 1 year ago Innate Pharma Secures €15M Sanofi Investment Capital Increase Innate Pharma Sanofi Investment BCMA ANKET Biotech Partnership
PRESS RELEASE published on 04/24/2025 at 07:35, 1 year ago Inside Information / Other news releases Innate Pharma announces €15M investment by Sanofi to strengthen collaboration and support pipeline execution. Closing of the capital increase expected on April 25, 2025 Investment Collaboration Sanofi Innate Pharma Pipeline Execution
BRIEF published on 04/23/2025 at 07:05, 1 year ago Innate Pharma Takes Back Rights and Sanofi Considers Investment Strategic Investment Sanofi Innate Pharma Acute Myeloid Leukemia CD123
PRESS RELEASE published on 04/23/2025 at 07:00, 1 year ago Inside Information / Other news releases Innate Pharma regains rights on CD123 targeting ANKET® as Sanofi plans strategic investment. SAR'579 (IPH6101) ongoing study shows promise in AML patients Strategic Investment Sanofi Innate Pharma CD123 Targeting SAR'579
BRIEF published on 04/16/2025 at 07:05, 1 year ago Innate Pharma General Meeting Announced for May 22, 2025 Shareholders Biotechnology General Meeting Innate Pharma Marseille
Published on 05/02/2026 at 21:00, 10 hours 8 minutes ago GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 1 day 5 hours ago Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 day 6 hours ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 day 7 hours ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 day 7 hours ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/03/2026 at 04:45, 2 hours 23 minutes ago GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype
Published on 05/02/2026 at 15:35, 15 hours 33 minutes ago Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Published on 05/01/2026 at 19:23, 1 day 11 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/30/2026 at 20:00, 2 days 11 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 2 days 11 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 2 days 12 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 2 days 12 hours ago Minutes of the Combined General Meeting held on April 30, 2026
